Fidaxomicin
Tier C — Watch / tradeFidaxomicin · all drugs expiring in 2028 →
Targets:RNAP
Brand:Dafclir, Dificid, Dificlir
Indications (approved):Clostridioides difficile infection, Enteritis, Diarrhoea
Regional status
Factories producing this API2
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
2 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
Frequently asked questions
What are the approved indications of Fidaxomicin?
Approved indications include: Clostridioides difficile infection, Enteritis, Diarrhoea.
When does the Fidaxomicin patent expire?
Based on public sources, the Fidaxomicin patent expires in 2028.
How many synthesis routes are recorded for Fidaxomicin?
1 synthesis routes are recorded; the shortest is 1 steps with 4.24 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Fidaxomicin intermediates?
All intermediates in Fidaxomicin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Fidaxomicin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29
